Ochre Bio’s Post

BIOVIIIx has been recognized as the Hemophilia Company of the Year In Europe by Life Sciences Review. BIOVIIIx is a family-run biotech firm that excels in haemophilia and rare diseases. Focusing on scientific research and global partnerships, it rapidly advances treatments and develops innovative solutions. The company invests in employee training, business modernisation and R&D, aiming for international growth through new business units and expanded therapeutic approaches "BIOVIIIx is grounded in ethical and human-centric values. Its decision-making process focuses on projects that directly benefit patients, often foregoing immediate financial gains. This patient-centric approach leads the company to go above and beyond standard practices." says Davide Rosiello, CEO The article will also be featured in the forthcoming special print edition of Hemophilia 2024. Read More : https://lnkd.in/gRB9nJiH #BiotechInnovation #ScientificResearch #HealthcareInnovation #InnovativeTherapies #PharmaResearch #EmployeeTraining

🚀 What an incredible event at Bristows LLP in the amazing Unilever Building by Blackfriars, London! 🌆 📆Over the last decade, #cellandgenetherapies have made remarkable progress, with deal-making in this space rising rapidly. Yesterday's panel event, hosted by Bristows, was an insightful deep dive into the latest opportunities and challenges involved in M&A, #VC, and licensing transactions in this revolutionary field. 💉⚖ The expert panel discussed crucial topics such as: 🔬 What makes these deals different from those for #smallmolecules or other #therapies? 💡 Top priorities for those looking to invest in or acquire #cell or #genetherapy businesses. 📊 M&A trends and lessons learned from licensing deals. 📜 The #regulatory landscape impacting these deals. 🏆 Key ingredients needed to make these deals a success. To reiterate a huge thank you to One Nucleus, Bristows, and all the fantastic panellists for making this event such a success: 🎤 Claire Smith, Bristows LLP 🎤 Jodie Albutt, Quell Therapeutics 🎤 Nuno Alves, PhD, Astellas Pharma 🎤 Graeme Fielder, AviadoBio 🎤 Pedro Correa de Sampaio, Neobe Therapeutics 🔬The insights shared were invaluable and will undoubtedly drive future innovation and collaboration in the cell and gene therapy space. Here's to more breakthroughs and successful deals ahead! 📈 🥳 All this aside it was excellent to network with amazing people like Claire Smith, Jake Rightmyer, Shay Kelly, Yasmin Dosanjh, Jenny Yu, Mo Cifci, Alex Denoon and Richard Dickinson 🧬 😕 Sorry I did not get to say hi to the superb Alicia Gailliez and Deborah Cockerill, but hope to catch up again soon 🎉 ⭐ The highlight of the evening, though, had to be meeting up with my old colleague Dr. Najam Shezad MRSC from our time at QCL. I think it must’ve been at least 12 years since we last worked together and although we’ve been In touch on LinkedIn, there’s nothing quite like an in-person unexpected meet! Once a colleague and friend always a colleague and friend 🤝 #CellTherapy #GeneTherapy #MandA #VentureCapital #Licensing #HealthcareInnovation #Bristows #OneNucleus #Biotech #LinkedIn Jamie Duncan Matt Burwood 👩🔬🧑⚖

Day 18 of the 30 - DAY Helix Biogen Challenge When we started the project for the development of the vaccine candidate, it was something I was so new to and I had to pay close attention to what was taught and what I needed to know. Individually, we will be given tasks and we had to deliver them as soon as possible. Knowing fully well that this was new to me, I had to do more findings and taught about things that will give me the results I needed and with the help of my friends and colleagues, I was able to achieve those tasks. Dr. Oladipo Elijah Kolawole (Ph.D) Helix Biogen Institute #HelixBiogenInstitute #HelixBiogenChallenge #ScientificChallenge

Excited to announce that I will be attending Bioeurope Spring, one of the most prominent biotech partnering conferences! Looking forward to connecting with industry leaders, exploring innovative collaborations, and staying up-to-date with the latest trends in the life sciences sector. If you'll be there too, I would love to meet up and discuss potential opportunities. See you at #BioEuropeSpring! #MilliporeCTDMO #Drugconjugate #smallmolecule #HPAPI #linkerpayload"

Beyond excited to share the news that #CreyonBio is presenting clinical data for AI-assisted antisense oligonucleotide drug discovery at the ASGCT meeting! It's been an incredible journey, and I'm extremely fortunate and proud to be a part of such an outstanding team. Thank you to everyone who has supported us along the way! 🌟 #ASGCT #BiotechInnovation #DrugDiscovery #CreyonBio Snippet from the Press Release:- ".....Within one year of project initiation in partnership with The TNPO2 Foundation, Creyon developed a novel allele-selective Locked Nucleic Acid (LNA) treatment candidate for an ultra-rare and severe neurological disease caused by a single nucleotide variant in the Transportin-2 (TNPO2) receptor, and an investigator-initiated clinical trial received approval to dose a patient........This treatment has been well-tolerated with no increase in inflammatory markers in the cerebrospinal fluid (CSF) or adverse changes on brain MRI scans. Notably, the patient experienced reduced seizure frequency after the second dose and regained developmental milestones including rolling, sustained attention and gaining novel skills such as tripod sitting and responsive babbling after the third dose......" https://lnkd.in/g3TA7FH9

At Goodland Pharma, our journey began with a profound passion for the triumphs of life science. Founded by visionaries deeply entrenched in the industry, we've cultivated global teams that have played pivotal roles in countless scientific breakthroughs. What sets us apart? Our seasoned expertise isn't just surface-level – it delves deep into your world, comprehending the intricate nuances of regulations and the critical factors that drive clinical trial success. Get started here: https://lnkd.in/g_z8FmWD #GoodlandPharma #TailoredSolutions #LifeScience #ClinicalTrials

🚀 Exciting Partnership Announcement with Eurofins Genomics 🚀 We are thrilled to share that Hurdle has partnered with Eurofins Genomics to revolutionise the development, accessibility, and implementation of complex biomarker technologies. This collaboration promises to drive advancements in fields ranging from drug discovery to healthcare and agriculture. By leveraging Hurdle's cutting-edge technology platform and Eurofins Genomics' extensive global laboratory network, we are setting new benchmarks for the speed and efficiency of omics testing across various industries. Our partnership is designed to enhance current systems, accelerate innovation, and bring about significant improvements in the application of complex biomarker technologies. This groundbreaking alliance breaks traditional boundaries, delivering substantial progress in basic research, consumer health, food security, and pharmaceuticals. As one of the first partnerships of its kind, we are proud to be at the forefront of advancing science and implementing complex biomarkers for the benefit of all. Dr. Tom Stubbs Co-founder of Hurdle, highlights the potential: "This partnership marks a watershed moment in omics technologies. It accelerates innovation, drastically improves global accessibility, and expands the applications of these technologies. From precision medicine to food security, we are supporting the best researchers in the world to deliver a brighter future for all.” Stay tuned for more updates as we embark on this exciting journey together! 🌟 #Innovation #Biomarkers #Healthcare #FutureOfScience #EurofinsGenomics

🎉 Celebrating Micro, Small, and Medium-Sized Enterprises Day! 🎉 Micro-, small-, and medium-sized businesses play a big role in economies, communities, and livelihoods around the world. At Genoskin, we're proud to be part of this vibrant ecosystem that drives #growth, fosters #innovation, and opens new markets and industries. Spotlight on our achievements: 🚀 This year, we were honored to be recognized as one of the "Champions de la Croissance 2024" (Growth Champions 2024) by Les Echos in collaboration with Statista. This prestigious recognition underscores our relentless commitment to pushing the boundaries of innovation and sustaining our growth in an ever-evolving industry. It's a testament to the trust and support from our incredible team, clients, and partners. 💡 Our dedication to innovation is at the core of what we do. Our cutting-edge project in vaccine immunoprofiling is just one example of how we're pioneering new approaches in the field of #drugdevelopment. 🌐 Genoskin is at the heart of disrupting traditional drug development processes by offering #nonclinical services that provide a viable alternative to animal testing. Our innovative skin research projects are paving the way for more ethical and effective solutions in the industry. On this special day, we celebrate the significant impact of MSMEs like ours in driving economic growth, fostering innovation, and shaping the future! 🌟

🚨𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝗡𝗲𝘄𝘀🚨 Creyon Bio and Cajal Neuroscience have announced a partnership to develop #Oligonucleotide-based medicines for Neurodegenerative Diseases. This collaboration tackles two major hurdles in drug development for neurodegenerative diseases. Cajal's cutting-edge platform pinpoints promising targets with incredible precision. Creyon Bio's innovative technology then allows Cajal to swiftly engineer safe and effective oligonucleotide-based therapies. Together, Creyon Bio and Cajal Neuroscience are pushing the boundaries of science to deliver life-changing treatments for millions struggling with neurodegenerative conditions.

BIO Deutschland celebrates its 20th anniversary BIO Deutschland e. V. celebrated its 20th anniversary on September 17. The association was founded two decades ago in Frankfurt am Main with the aim of supporting innovative biotech start-ups. Today, BIO Deutschland e. V. Deutschland represents the interests of more than 380 members of all maturity levels and sizes, covering the entire spectrum of the #biotechnology sector, from medical biotechnology with therapy and diagnostics development, contract research and production, to industrial biotechnology including nutrition and #bioinformatics or AI and the associated industry clusters. Oliver Schacht, Chairman of the Board of BIO Deutschland e. V., said: “We can look back on a 20-year success story with BIO Deutschland. The founding of the association gave innovative start-ups and small and medium-sized biotech companies a voice. Our industry has grown continuously over the last 20 years and continues to have great growth potential. Biotechnology is also a future technology with high added value for Germany. The sector has developed in a correspondingly diverse way. Some start-ups have become hidden champions or world-renowned companies. New start-ups with innovative ideas are added every year. As a platform technology, biotechnology is the basis for companies with numerous different business models. We can clearly be part of a positive future, as long as the framework conditions in Germany and Europe allow, the Biotech industry will continue becoming a key industry in Germany.”